University of Oxford unveils new vaccine development partnership
26 November 2024
Oxford Cancer, the Oxford Vaccine Group and the Pandemic Sciences Institute have announced a new collaboration with Belgian biotech innovator Univercells.
Novel antibody platform tackles viral mutations
1 November 2024
Scientists in the Nuffield Department of Medicine and the Icahn School of Medicine at Mount Sinai have developed an innovative antibody platform aimed at tackling one of the greatest challenges in treating rapidly evolving viruses like SARS-CoV-2: their ability to mutate and evade existing vaccines and therapies.
T-cell aerosol immunisation as path to universal influenza vaccine
23 October 2024
In a new study, published in NPJ Vaccines, researchers from the Pandemic Sciences Institute and The Pirbright Institute have generated new evidence supporting the development of a universal influenza vaccine.
Adán Pinto-Fernández Secures Prestigious 2-Year Grant from Boehringer Ingelheim
5 September 2024
CAMS Oxford Institute Group Leader and Career Development Fellow, Adán Pinto-Fernández, has been awarded a highly competitive 2-year project grant by Boehringer Ingelheim through their Open Innovation Portal initiative, opnMe.
ORTU awarded £2.8m to study treatment for pleural infection
30 July 2024
The Oxford Respiratory Trials Unit (ORTU) at the Nuffield Department of Medicine has been awarded a £2.8 million grant from the National Institute for Health and Care Research Health Technology Assessment (NIHR HTA) to conduct the MIST4 study.
Peijun Zhang elected to European Molecular Biology Organization membership
16 July 2024
120 scientists from across Europe and beyond have been elected to the European Molecular Biology Organization (EMBO) membership, an honour that celebrates research excellence and outstanding achievements in the life sciences, including Dr Peijun Zhang from the Nuffield Department of Medicine.
Sepsis patients could get the right treatment faster based on their genes
21 June 2024
Sepsis patients could be treated based on their immune system’s response to infection, not their symptoms. New research uncovers how different people respond to sepsis based on their genetic makeup, which could help identify who would benefit from certain treatments and lead to the development of targeted therapies.
Novel data method sheds light on hidden patterns of kidney inflammation
20 June 2024
Globally kidney disease is forecast to be the 5th leading cause of death by 2040, and in the UK more than 3 million people are living with the most severe stages of chronic kidney disease. Chronic kidney disease is often due to autoimmune damage to the filtration units of the kidney, known as the glomeruli, which can occur in lupus, a disease which disproportionally affects women and people of non-white ethnicities, groups often underrepresented in research. Treatment options are limited, can have life threatening side-effects and often don’t slow the disease, which can then progress to end stage, requiring dialysis or a kidney transplant.
Three CAMS Oxford Institute Principal Investigators elected to the Fellowship of the Academy of Medical Sciences
21 May 2024
Professor Teresa Lambe OBE, Professor Julian Knight & Professor Jane McKeating have been elected as Fellows of the Academy of Medical Sciences, one of the most prestigious awards in the field.
Nature Nanotechnology study introduces new and improved version of all-in-one coronavirus vaccine
7 May 2024
CAMS Oxford Institute researchers publish an improved version of a novel all-in-one vaccine against coronavirus threats in Nature Nanotechnology.
Ono Pharmaceutical Co collaborates with CAMS Oxford Institute & Centre for Medicines Discovery for translational research
1 May 2024
The Centre for Medicines Discovery (CMD) and CAMS Oxford Institute (COI) at NDM, has recently partnered with Ono Pharmaceutical Co (Ono) to validate and develop novel targets in a bid to discover innovative medicines.
NLRP3 Inflammasome “DUBbed” by UCH-L1, affecting IL-1β production in macrophages and microglia
30 April 2024
A Cell Reports study led by Prof. Benedikt Kessler provides an intricate time-resolved molecular map of different phases of NLRP3 inflammasome activation and unveils ubiquitin C-terminal hydrolase 1 (UCH-L1) as a modulator of NLRP3 inflammasome assembly and IL-1β production.
CAMS Oxford Institute Symposium held in Oxford
29 April 2024
The annual CAMS Oxford Institute Symposium was held on Monday 15th April 2024 in the Richard Doll Building on Old Road Campus for a full day of scientific talks, poster presentations & networking.
Novel pairing of integrins improves action of T cells on cancer cells to control tumour growth
2 April 2024
New research published in Nature Immunology showcases the collaborative efforts of CAMS Oxford Institute researchers to describe a novel pairing of integrins which could improve T cell control of cancer.
Ricardo Fernandes awarded a Cancer Research UK Immunology Project Award
8 March 2024
CAMS-Oxford Institute Principal Investigator, Ricardo Fernandes, has been awarded a competitive grant from Cancer Research UK to study anti-tumour T cell responses.
Assistant Professor Yunlong Cao visits CAMS Oxford Institute
20 February 2024
On 1st- 2nd of February 2024, Assistant Professor Yunlong Cao from Peking University, Beijing, China, visited the Chinese Academy of Medical Sciences Oxford Institute (COI), Nuffield Department of Medicine (NDM), University of Oxford.
Longitudinal study shows how immune responses to SARS-CoV-2 decline over time
22 December 2023
In a study led by CAMS Researchers, patients were tracked for two years post COVID-19 infection in a bid to understand how memory immune responses decline over time and give insight into vaccination & booster strategies.
2023 Round Up
21 December 2023
A note from our Directors on the success of 2023 for the CAMS Oxford Institute.
Super-Enhancer Components Work as a Team to Increase Gene Expression of Alpha-globin
14 December 2023
Researchers from Oxford University & New York University have revealed how super-enhancers work to increase gene expression of the α-globin gene.
Novel processing enzyme for ISG15 discovered
7 December 2023
Researchers from the CAMS Oxford Institute and NDM Target Discovery Unit, including Prof. Benedikt Kessler and Dr. Adán Pinto-Fernández, have collaborated with the team of Dr. Paul Geurink and Dr. Aysegul Sapmaz from Leiden University to investigate an important interferon-stimulated gene, ISG15.